拉尔杰夫抑制剂抑制RAS驱动的胰腺癌和转移
Howard Donninger1, Rachel Ferrill2, Becca von Baby2
1Department of Medicine, University of Louisville, Louisville, Kentucky, USA.
The Journal of biological chemistry
|October 10, 2025
概括
研究人员开发了第一个针对泛拉斯类 (RAL) 小GTPase交换因子 (RALGEF) 的小分子抑制剂. 这种化合物抑制了RAS/RAL信号,并在临床前模型中显示出抗瘤作用,为RAS驱动的癌症提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在癌症中,RAS基蛋白经常被激活,但直接抑制剂面临诸如耐药性等挑战.
- 针对RAS下游效应因子 (RAF,PI-3激酶,RALGEF) 是一个替代策略.
- 现有的RAF和PI-3激酶抑制剂具有有限的临床疗效;尽管在RAS驱动的转化中具有重要作用,但RALGEF抑制剂尚未得到充分研究.
研究的目的:
- 开发和描述第一个针对泛RALGEF的小分子抑制剂.
- 为了评估抑制剂对RAS/RAL信号的特异性.
- 在临床前癌症模型中评估该化合物的抗瘤功效.
主要方法:
- 开发一种新的小分子泛RALGEF抑制剂.
- 对RAS/RAL信号通路的抑制剂特异性的评估.
- 在异种移植和患者衍生异种移植 (PDX) 模型中评估抗瘤活性.
主要成果:
- 这种新型化合物作为泛-RALGEF的特定抑制剂.
- 该抑制剂有效地抑制了RAS/RAL信号传递.
- 在临床前异种移植模型中观察到显著的抗瘤效应,包括PDX模型.
结论:
- 这种类别中的第一个泛RALGEF抑制剂在向RAS驱动的瘤方面表现有前途.
- 该化合物表现出特定抑制RAS/RAL信号和抗瘤活性.
- 这种方法可能会为各种RAS驱动的癌症带来更有效的治疗方法.
相关概念视频
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Small GTPases - Ras and Rho
5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K


